Clinical TrialJun 18, 2026, 09:21 AM
Longeveron Alzheimer's Trial Data Accepted for AAIC Presentation
AI Summary
Longeveron Inc. announced that additional analysis of data from its Phase 2a clinical trial evaluating laromestrocel for mild Alzheimer's disease has been accepted for a poster presentation at the 2026 Alzheimer's Association International Conference (AAIC). The presentation is scheduled for July 13, 2026, in London. Previous results from the CLEAR MIND Phase 2a trial, supporting laromestrocel's therapeutic potential, were published in Nature Medicine in March 2025.
Key Highlights
- Additional analysis of Phase 2a clinical trial data for laromestrocel in mild Alzheimer's disease accepted for presentation.
- Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) on July 13, 2026.
- The presentation topic is "Laromestrocel in Mild Alzheimer’s Disease: Additional Phase 2a Clinical Data Analysis."
- Results from the CLEAR MIND Phase 2a trial were previously published in Nature Medicine in March 2025.
- Laromestrocel has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS.
- Laromestrocel also holds FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for Alzheimer's disease.
Price Impact
More from LGVN